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Calcium/calmodulin-dependent protein kinase II (CaMKII) activity has been shown to
contribute to arrhythmogenesis in a remarkably broad range of cardiac pathologies. Several
of these involve signiﬁcant structural and electrophysiologic remodeling, whereas others
are due to speciﬁc channelopathies, and are not typically associated with arrhythmogenic
changes to protein expression or cellular and tissue structure. The ability of CaMKII to
contribute to arrhythmia across such a broad range of phenotypes suggests one of two
interpretations regarding the role of CaMKII in cardiac arrhythmia: (1) some CaMKII-
dependent mechanism is a common driver of arrhythmia irrespective of the speciﬁc
etiology of the disease, or (2) these different etiologies expose different mechanisms by
which CaMKII is capable of promoting arrhythmia. In this review, we dissect the available
mechanistic evidence to explore these two possibilities and discuss how the various
molecular actions of CaMKII promote arrhythmia in different pathophysiologic contexts.
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INTRODUCTION
Calcium/calmodulin-dependent protein kinase II (CaMKII) is
a key regulator of excitation-contraction coupling in cardiac
myocytes. As described in detail elsewhere in this special issue,
CaMKII modulates the function and expression of numerous
myocyte ion channels and calcium handling proteins (Figure 1).
These include NaV1.5, the L-type Ca2+ channel (LCC), several
potassium channel subunits, the cardiac isoform of the ryanodine
receptor (RyR2), and phospholamban (PLN; Bers and Grandi,
2009). Many of the effects at these targets are proarrhythmic
(Swaminathan et al., 2012; Fischer et al., 2013b), although some
are antiarrhythmic by conventional paradigms (Tessier et al., 1999;
El-Haou et al., 2009; Cheng et al., 2012), and therefore need to be
considered in combination. Integrating these pleiotropic effects
is further complicated by the temporal, spatial, and biochemi-
cal complexities of CaMKII activation (see articles herein from
Erickson, 2014 and Gray and Heller Brown, 2014) in the intact
myocyte. Thus, deciphering how CaMKII activity contributes to
arrhythmia in any disease context is complex and non-intuitive.
These complexities notwithstanding, the potential for CaMKII
inhibition to reduce arrhythmogenic outcomes has been demon-
strated in animal models of a remarkably broad range of human
diseases: from genetic channelopathies, such as catecholaminer-
gic polymorphic tachycardia (CPVT), to etiologically complex
pathologies such as heart failure, atrial ﬁbrillation (AF), and
ischemia/reperfusion injury (I/R). For this reason, and in addi-
tion to its potential as a target for anti-hypertrophic therapy,
CaMKII has become a leading candidate for anti-arrhythmic
targeting in the heart. Here we use this diverse range of dis-
ease models to develop a conceptual hierarchy of mechanisms
in CaMKII-mediated arrhythmia. Speciﬁcally, we interrogate
whether current evidence suggests thatCaMKII promotes arrhyth-
mia via multiple mechanisms, each of which can be recruited by
particular disease etiologies, or alternatively, that CaMKII drives
the same terminal mechanism irrespective of the speciﬁc under-
lying pathology. We contend that, while CaMKII disrupts ionic
homeostasis and impairs repolarization through its actions at
many different targets, the available evidence suggests that these
mechanisms eventually converge to result in spontaneous Ca2+
release (SCR) from the sarcoplasmic reticulum (SR) and delayed
afterdepolarizations (DADs). Thus we suggest that this is a dom-
inant terminal mechanism of CaMKII-mediated arrhythmia, and
may explain why experimental manipulation of CaMKII phos-
phorylation at RyR2 has proven effective in many models of
arrhythmogenic disease.
CELLULAR MECHANISMS OF CaMKII-MEDIATED
ARRHYTHMIA
A key feature of CaMKII signaling in arrhythmia is the presence
of several positive feedback mechanisms, whereby CaMKII tar-
get phosphorylation results in changes to Ca2+ homeostasis (or
metabolism) that further activate the kinase. These mechanisms
are likely to contribute both during acute homeostatic challenge,
such as β-adrenergic stimulation, and to the chronic disruption of
ionic homeostasis in acquired disease. Figure 2 shows two major
forms of this feedback. Hyper-phosphorylation of LCCs, PLN,
(Figure 3A, mechanism 1) and NaV1.5 (Figure 3A, mechanism 2)
increase whole-cell Ca2+ load either directly (LCC and PLN) or
by impairing forward mode Na+/Ca2+ exchange (NaV1.5). This
both promotes SCR in and of itself, and also further activates
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FIGURE 1 | CaMKII regulation of cardiomyocyte electrophysiology and
Ca2+ handling. CaMKII exerts acute (black) and transcriptional (blue)
regulation ([10]-Wu et al., 2006; [11]-Backs et al., 2006) of many key proteins
in cardiac electrophysiology and calcium handling. Acute phosphorylation of
LCCs by CaMKII potentiates ICaL and slows inactivation ([1]-Yuan and Bers,
1994). Transcriptional effects are less established but likely downregulate
channel expression ([2]-Ronkainen et al., 2011). Phosphorylation of RyR2 by
CaMKII promotes Ca2+ release from the SR and is implicated in many
proarrhythmic contexts ([3]-Witcher et al., 1991; [4]-Wehrens et al., 2004).
Available data suggest CaMKII transcriptional regulation promotes Ca2+
extrusion from the cell by increasing NCX expression and decreasing
SERCA ([6]-Mani et al., 2010; [5]-Lu et al., 2011). Ito and IK1 are enhanced by
acute CaMKII phosphorylation ([7]-Li et al., 2006), and transcriptional
downregulation of these currents is a well-established effect of long term
CaMKII activity. This reduces repolarization reserve and may destabilize
resting membrane potential ([8]-Wagner et al., 2009). Acute regulatory
effects of CaMKII on NaV1.5 enhance inactivation, decrease availability and
potentiate INaL, but again any transcriptional regulation is unclear
([9]-Wagner et al., 2006). Acute phosphorylation of PLN disinhibits SERCA
and enhances SR Ca2+ reuptake ([12]-Karczewski et al., 1997).
CaMKII, which independently drives SCR through phosphory-
lation of RyR2 (Figure 3A, mechanism 3; Wehrens et al., 2004).
While it is not shown in Figure 2, the increased cytosolic Ca2+
also causes mitochondrial Ca2+ loading and probably invokes a
third positive feedback loop involving ROS-dependent CaMKII
activation (see Joiner and Koval, 2014 in this issue). Of course,
the actions of CaMKII at LCCs, INa, and certain potassium cur-
rents also directly result in proarrhythmic changes to the action
potential (AP), including prolonged repolarization and early after-
depolarizations (EADs, Figure 3B; Guo et al., 2006). Thus, even at
the level of integrated physiological outcomes, there are a number
of CaMKII-dependent mechanisms capable of disrupting cardiac
ionic homeostasis and electrophysiology. Our focus here is to
understand which of these predominates in experimental models
of human disease.
ARRHYTHMOGENIC INFLUENCE OF CaMKII IN CONGENITAL
HEART DISEASE
The last 20 years have witnessed rapid progress in understanding
the molecular and genetic basis of congenital arrhythmogenic dis-
eases (Curran et al., 1995; Cerrone et al., 2012; Napolitano et al.,
FIGURE 2 | CaMKII positive feedback mechanisms involved in cardiac
disease. As a Ca2+ regulated kinase, CaMKII is sensitive to any
physiological mechanism that alters intracellular Ca2+ cycling. Many of its
own catalytic actions result in such alterations, and two gain-of-function
effects that create positive feedback by enhancing Ca2+ cycling occur at
ICaL (left) and INa (right). CaMKII regulation of INa is thought to increase
intracellular Na+ via enhanced late INa, which in turn reduces the
thermodynamic potential for Ca2+ extrusion via NCX. CaMKII regulation of
ICaL more directly enhances Ca
2+ cycling by increasing Ca2+ inﬂux
through slightly elevated peak current and slowed inactivation.
2012). Somewhat surprisingly, CaMKII activity and hyperactivity
have been shown to contribute in many experimental models of
these diseases, even those with minimal or undetectable remodel-
ing of myocardial structure. As such, these models offer a unique
perspective of how CaMKII promotes arrhythmia in the absence
of sequelae associated with structural disease. In this section, we
reviewexamples of CaMKII involvement in congenital arrhythmo-
genic disease, and identify key questions that remain for deﬁning
the roles, limits, and potential for therapeutic targeting of CaMKII
in these contexts. Impressively, the available data suggest that
CaMKII-dependent regulation of RyR2 is an important contribu-
tor to arrhythmogenesis in the majority of these congenital disease
models. Here we focus speciﬁcally on how this regulation con-
tributes to electrophysiologic instability, and suggest the review
contributed by Camors and Valdivia (2014) for those interested in
a more mechanistic description of CaMKII-dependent regulation
of RyR2.
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
The autosomal dominant form of CPVT has become the proto-
typical disease of RyR2-mediated arrhythmia, and accounts for
at least half of all positive CPVT diagnoses (Priori et al., 2002).
This channelopathy results from a family of RyR2 mutations
that cause channel hyperactivity due to increased receptor Ca2+
sensitivity. The outstanding physiological ramiﬁcation of these
mutations is increased myocyte susceptibility to SCR and DADs
during catecholamine-induced Ca2+ overload. As such, β-blocker
therapy is a front-line treatment for CPVT patients. However, in
∼50%of cases, episodes of VT still present during β-blockade, and
more aggressive treatment (including ICD implantation) is often
required (Priori et al., 2002; Watanabe and Knollmann, 2011).
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies May 2014 | Volume 5 | Article 110 | 2
Vincent et al. CaMKII-mediated arrhythmia mechanisms
FIGURE 3 | Mechanisms of CaMKII-mediated afterdepolarizations.
(A) Pathological CaMKII regulation can trigger diastolic SR Ca2+ release
resulting in electrogenic Ca2+ extrusion by NCX and DADs (red arrows).
This results from pro-arrhythmic CaMKII regulation at multiple target
proteins, which together drive 3 mechanisms through which CaMKII
promotes SCR. First, CaMKII elicits gain-of-function effects at ICaL and
SERCA (via PLN-mediated disinhibition), thereby increasing Ca2+ inﬂux and
resulting in Ca2+ overload (mechanism 1, blue arrows). Second, CaMKII
hyper-phosphorylation of NaV1.5 can elevate intracellular Na
+ resulting in
Na+-induced Ca2+-overload by decreasing Ca2+ efﬂux through NCX
(mechanism 2, black arrows). Third, CaMKII directly phosphorylates RyR2,
which has been shown to promote SCR and has been strongly implicated
in a number of different models of arrhythmogenic disease (mechanism 3,
red arrow). (B) CaMKII phosphorylation of depolarizing currents reduces
repolarization reserve and promotes EADs (red arrows) in certain disease
contexts. Altered LCC gating due to CaMKII hyper-activity can elicit EADs
by increasing and prolonging ICaL (mechanism 4, blue arrows). NaV1.5
phosphorylation increases INaL and may lead to non-equilibrium reactivation
of INa (mechanism 5, black arrows), both of which can trigger EADs.
Thus, efforts to deﬁne additional effective pharmacotherapeutic
approaches for this disease remain a high priority.
Conceptually, CaMKII presents an attractive target in CPVT
because its established actions at various Ca2+ handling pro-
teins would all be expected to exacerbate arrhythmia resulting
from RyR2 hyperactivity. Indeed, transgenic overexpression of
CaMKIIδC in the R4496C (+/−)mousemodel of CPVTworsened
the arrhythmia phenotype and increased mortality (Dybkova
et al., 2011). However, few studies have assessed whether, and
how, CaMKII activity contributes to arrhythmia in CPVT. Liu
et al. (2011) showed that both chronic and acute administration
of KN-93 dramatically reduced the incidence of arrhythmia in
the R4496C (+/−) mouse. More speciﬁc CaMKII blockade by
autocamtide-2 related inhibitory peptide (AIP) also markedly
decreased the incidence of SCR, DADs, and triggered activity
in isolated R4496C (+/−) ventricular myocytes (VMs). Inter-
estingly, while AIP did remove signature effects of CaMKII on
Ca2+ handling (e.g., frequency dependent acceleration of relax-
ation, FDAR), it did not achieve those effects by reducing SR Ca2+
load at any baseline pacing frequency or during isoproterenol
(Iso) challenge. Thus, the antiarrhythmic actions of CaMKII
blockade were unlikely to result from reduced SR or whole cell
Ca2+ overload. Instead, they appeared to rely on reduction
of CaMKII-induced RyR hyperactivity (Figure 3A, mechanism
3), as measured by triggered fractional release, and spark fre-
quency. AIP reduced both of these measures in R4496C (+/−)
myocytes, particularly during Iso challenge, and KN-93 reduced
RyR2 phosphorylation at the established CaMKII site, Ser-2814.
Thus, this study suggests that, even in myocytes already express-
ing hyperactive mutant RyR2, CaMKII phosphoregulation of this
critical SR Ca2+ release channel may further contribute to in vivo
arrhythmogenesis.
CONGENITAL LONG QT SYNDROME
Recent work has suggested that CaMKII is involved in several
rare forms of congenital long QT (LQT) syndrome. Importantly,
CaMKII mutations have not been established as the source of
genetic susceptibility in these, or to date, any congenital arrhyth-
mogenic disease. Rather, in all existing studies, CaMKII exerts its
proarrhythmic inﬂuence by exacerbating the effects of disease-
associated mutations occurring in other electrophysiologic or
calcium handling proteins, many of which are CaMKII targets.
Ankyrin-B syndrome/LQT4
After remaining elusive for over 10 years, the molecular basis
for type 4 LQT syndrome was identiﬁed in 2003 as a family of
loss-of-function mutations in Ankyrin-B (Mohler et al., 2003).
The electrophysiologic dysfunction associated with these muta-
tions is broad, and often also involves sinus bradycardia and
catecholamine-induced arrhythmia, but is not associated with
gross structural defects. LQT is relatively mild in most cases,
and absent for some mutations even though individuals harbor-
ing these mutations remain arrhythmia susceptible (Mohler et al.,
2004). Owing to this spectrum phenotype and clear molecular
source, LQT4 is now often referred to as Ankyrin B syndrome
(Yong et al., 2003). Heterozygous deletion of AnkB in the mouse
recapitulates many signatures of human LQT4 (Mohler et al.,
2003), including inducible polymorphic VT, and this model
has now been used extensively to study mechanisms of the
disease.
In neonatal AnkB(+/−) myocytes, LQT4 mutations consis-
tently reduce expression and disrupt localization of themyocardial
Na+/Ca2+ exchanger (NCX1), Na+/K+ ATPase (NKA), and inos-
itol triphosphate (IP3) receptor (Mohler et al., 2003, 2004). In
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adult myocytes, these changes promote signature arrhythmo-
genic changes including AP prolongation (DeGrande et al., 2012),
a prominent increase in Ca2+ waves (Camors et al., 2012) and
afterdepolarizations (DeGrande et al., 2012). The mechanistic link
between altered AnkB molecular anchoring and these arrhythmo-
genic outcomes is not fully established, but recent studies sum-
marized below have suggested an important role for altered Ca2+
homeostasis, and particularly for CaMKII-dependent regulation
of RyR2.
Given the observed changes to expression and distribution
of major Na+ transporters, Camors et al. (2012) investigated
whether altered Na+ handling could explain arrhythmogenicity
in AnkB(+/−) myocytes. They found that, while maximal NKA
function was depressed, this had little impact on measures of
basal or challenged Na+ homeostasis, and did not increase dias-
tolic [Ca2+]i. However, AnkB(+/−) myocytes did exhibit slightly
increased SR Ca2+ load, enhanced Ca2+ transient amplitude and
fractional release, and a marked increase in spark frequency and
Ca2+ waves. Soon after, the same group was able to show that
these effects are associated with RyR2 hyperactivity and increased
phosphorylation of RyR2 at the primary CaMKII site, S2814
(DeGrande et al., 2012). These effects could be normalized by
crossing the AnkB(+/−) mouse with one expressing the CaMKII
inhibitory peptide, AC3-I. These mice were also resistant to both
cellular afterdepolarizations and organ level arrhythmia present
in the AnkB(+/−) mice during adrenergic challenge (DeGrande
et al., 2012).
While the authors acknowledged that these RyR2 effects are
one component of what are probably many alterations associ-
ated with AnkB loss-of function, the observed changes in Ca2+
handling are consistent with a mechanism involving RyR2 hyper-
activity (Camors et al., 2012). Because AnkB is not known to
anchor CaMKII itself, the authors instead suggested that loss of
AnkB may have disrupted local phosphatase activity because pro-
tein phosphatase 2A is a known binding partner of AnkB and
regulator of RyR2 phosphorylation.
Timothy syndrome/LQT8
The extremely rare LQT8, more frequently referred to as Timothy
syndrome (TS), results from substitution mutations in the alpha
subunit (CaV1.2) of the cardiac L-type calcium current (ICaL).
Only two mutations have been described to date, and both replace
glycine residues with either arginine (pos. 406) or serine (pos. 402;
Splawski et al., 2004, 2005). These mutations profoundly impair
voltage-dependent inactivation of ICaL (VDI), and this is gener-
ally accepted to be the proximal molecular dysfunction associated
with the disease (Barrett and Tsien, 2008). The cardiac signatures
of TS include a range of cardiac structural defects and markedly
prolonged ventricular repolarization (Splawski et al., 2004, 2005).
Supraventricular arrhythmia has also been noted, particularly
AV block (Marks et al., 1995), but ventricular arrhythmogene-
sis is the most serious presentation of the disease, and most TS
patients experience life-threatening events in the ﬁrst years of
life (Splawski et al., 2004). The existence and severity of the TS
phenotype has forced clinicians and scientists to broadly recon-
sider the importance of VDI in normal and pathologic cardiac
electrophysiology.
Since the original mechanistic descriptions from Splawski et al.
(2004, 2005), a number of experimental models have been devel-
oped to investigate how these point mutations destabilize cardiac
electrophysiology. In general, those models have provided com-
pelling (albeit not entirely consistent) evidence for the involvement
of CaMKII. Erxleben et al. (2006) were the ﬁrst to suggest a
role for CaMKII, and observed that heterologous expression of
TS-mutated (G406R) rabbit CaV1.2 yielded LCCs exhibiting more
frequent prolonged openings (mode-2 gating). In noticing that
this substitution also created a consensus site forCaMKII at nearby
rabbit Ser-439 (homologous to human Ser-409), they hypothe-
sized that CaMKII activitymay be required for bothmode-2 gating
and slowed macroscopic inactivation of ICaL in TS. CaMKII inhi-
bition by KN-62, and genetic ablation of the putative CaMKII
phosphoacceptor (S439A) indeed eliminated the increased intrin-
sic mode-2 openings of the mutant channels in that study. Thiel
et al. (2008) extended this work to adult VMs by double-mutating
CaV1.2 to include both G406R and resistance to dihydropiridine
inhibition via T1066Y. This permitted the authors to modulate
the contribution of endogenous LCCs to macroscopic ICaL via
nifedipine, and thereby study the effects of the loss of ICaL control,
independent of differences in peak ICaL. Unlike Erxleben et al.
(2006), they were unable to observe a requirement for CaMKII
in the loss of VDI accompanying the G406R mutation. However,
they did observe an interaction between VDI loss and CaMKII,
whereby TS myocytes exhibited greater ICa facilitation than WT,
and this could be removed through peptide blockade of CaMKII
via AC3-I. To explain this they suggested that Ca2+ loading due to
impaired VDI caused enhanced secondary activation of CaMKII,
which in turn exaggerated ICa facilitation. They also observed a
pronounced increase in SCR and DADs, both of which could
be prevented by AC3-I. As a result they reasoned that DADs
occurring secondary to Ca2+ overload may reﬂect the domi-
nant arrhythmogenic role of CaMKII in TS, and mathematical
modeling supported this contention. Thus, in VMs, CaMKII acti-
vation may compound the effects of TS mutations by enhancing
ICaL facilitation in response to impaired VDI and increased Ca2+
inﬂux.
Further cardiac-speciﬁc models of TS have now been devel-
oped, most notably the G436R transgenic mouse developed by
Cheng et al. (2011). This model exhibits increased CaV1.2 expres-
sion, and the entirety of this increase (∼40%) is due to expression
of the G436R transgene. Somewhat surprisingly this additional
CaV1.2 does not increase peak ICaL in these mice but does slow
VDI in the expected manner, and intriguingly, this effect required
the anchoring proteinAKAP150. To explain this result, the authors
suggest that AKAP150 provides a key structural link among LCCs
within the dyadic ensemble, and they provide evidence that, in the
presence of G436R-mutated channels, AKAP150 promotes cou-
pled gating of LCCs and increases mode-2 behavior. Similarly to
Thiel et al. (2008), Yarotskyy et al. (2009), and Cheng et al. (2011)
observed that slowed inactivation in this model is not impacted by
CaMKII inhibition, and therefore suggest that the gating effects
underlying TS are probably not reliant upon G436R-mediated
creation of a CaMKII phosphorylation site at Ser-439/409. They
did, however, observe markedly enhanced Ca2+ cycling, pro-
longed AP duration, and exaggerated susceptibility to cellular
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afterdepolarizations. These effects were conﬁrmed in a recent and
more detailed study of Ca2+ handling in these mice (Drum et al.,
2014), and again like Thiel et al. (2008) the authors conclude that
Ca2+ overload and SCR are the likely terminal mechanisms of
arrhythmogenesis in this model.
In summary, these investigations suggest that CaMKII plays an
important role inTS arrhythmogenesis, but at least inVMs it seems
probable that this accompanies Ca2+ overload secondary to the
intrinsic effects of the TS mutations on LCC gating. An important
qualiﬁer here is that, to date, all experiments suggesting this role
for CaMKII have been conducted in primary cardiomyocytes from
rodents. The rapid repolarization of these cells probably biases
arrhythmogenic mechanisms away from disrupted repolarization
and toward SCR and arrhythmia arising during diastole. Thus,
similarly detailed investigations in large mammalian myocytes
remain desirable for clarifying if changes in ICaL gating are capa-
ble of playing a more direct role in human TS arrhythmia, and
if CaMKII still contributes in a similar manner and to a similar
degree.
Phosphomimetic mutation of NaV 1.5
CaMKII is an established regulator of the myocardial Na+ cur-
rent (INa), and simultaneously potentiates late INa (INaL) while
decreasing channel availability (Herren et al., 2013).While the spe-
ciﬁc phosphorylations required for these effects remain debated,
available evidence suggests that either or both Ser-571 and Ser-
516 may be key sites (Hund et al., 2010; Ashpole et al., 2012;
Koval et al., 2012; Herren et al., 2013), and it is generally agreed
that the I-II intracellular linker is the critical phosphoregulatory
domain.
An interesting line of investigation has suggested that mutation
of residues immediately adjacent to Ser-571 are associated with
congenital disease, and may result in phosphomimetic effects at
INa. Two mutations, A572D and Q573E, were originally uncov-
ered by genetic screening of Romano-Ward syndrome probands,
and therefore thought to be novel forms of LQT3 (Paulussen
et al., 2003; Tester et al., 2005). The A572D mutation has since
been dismissed as an independent source of LQT3 susceptibility,
but may still be associated with arrhythmogenic cardiac diseases
because it cosegregateswith the established arrhythmogenicmuta-
tion H558R (Tester et al., 2010). Having previously identiﬁed
Ser-571 as a potential site for CaMKII regulation, Koval et al.
(2012) recently investigated whether the functional effects of these
mutations exhibited any dependence on CaMKII activity. They
showed that heterologous expression of either A572D or Q573E
recapitulated CaMKII-dependent effects at INa. Neither constitu-
tively active CaMKII nor blockade of endogenous CaMKII altered
these effects, suggesting that they are autonomous to the mutant
NaV1.5 and independent of additional CaMKII phosphoregula-
tion. Further, the mutant gating defects could be reconstituted in
primary mouse VMs transfected with channels sensitive to low
dose tetrodotoxin to allow silencing of the exogenous NaV1.5.
While conﬂicting results from other groups (Tester et al., 2010;
Ashpole et al., 2012) suggest that these ﬁndings require further
interrogation, they provide the ﬁrst evidence that CaMKII reg-
ulation of INa may be sufﬁcient to induce an arrhythmogenic
phenotype in the absence of structural or ischemic disease.
ARRHYTHMOGENIC INFLUENCE OF CaMKII IN ACQUIRED
HEART DISEASE
An extensive literature describes the arrhythmogenic mechanisms
attributable to CaMKII hyperactivity in acquired heart disease.
A large portion of this is related to heart failure, but signiﬁ-
cant effort has also been invested in AF and ischemia/reperfusion
challenge (I/R). The CaMKII-dependent mechanisms involved
in AF and I/R are detailed separately in this issue by Heijman
et al. (2014) and Bell et al. (2014) and we direct the interested
reader to those comprehensive treatments. For the purposes
of this review it sufﬁces to note that recent studies of AF
and I/R mechanisms in mice and humans have again impli-
cated RyR2 dysregulation, and SR Ca2+ handling in general
(Said et al., 2008, 2011; Voigt et al., 2012; Purohit et al., 2013).
These aspects are consistent among the various acquired dis-
ease even though other important pathological conditions differ.
For example, some signature electrophysiologic alterations appar-
ent in AF (Nattel et al., 2008), such as shortened APD and
more negative resting potential, are precisely the opposite of
the alterations present in failing VMs (Tomaselli and Marbán,
1999).
As might be expected of the pathologic complexity in acquired
disease, the range of CaMKII-dependent mechanisms thought to
contribute to arrhythmia is also broader than for congenital dis-
ease. Speciﬁcally, CaMKII has been shown to contribute to Na+
overload in heart failure (Figure 3A, mechanism 2), and several
studies have suggested thatCaMKII effects at ICaL may be sufﬁcient
to directly destabilize electrophysiology in the failing ventricle
(Figures 3A,B). An additional feature of CaMKII-dependent
arrhythmia in heart failure and AF, and probably in acquired
disease in general, is the importance of CaMKII-oxidation as a
source of kinase hyperactivity (Luczak and Anderson, 2014; see
also the review by Erickson, 2014 in this special issue). This mode
of CaMKII activation appears to be particularly important in sinus
node (SN) dysfunction accompanying heart failure (Swaminathan
et al., 2011), in AF (Purohit et al., 2013), and diabetic cardiomy-
opathy (Luo et al., 2013). Finally, one of the most important
roles that CaMKII plays in acquired disease is as a controller of
the expression of several key ion channels and transporters, and
many disease-associated changes in expression of these proteins
appear to require CaMKII. The best-described of these involve K+
currents, namely the transient outward current (Ito) and inward
rectiﬁer current (IK1; Wagner et al., 2009; reviewed elsewhere in
this issue by Mustroph et al., 2014), but this transcriptional reg-
ulation may also extend to ICaL (Ronkainen et al., 2011), NCX1
(Mani et al., 2010), and SERCA2 (Lu et al., 2011).
HEART FAILURE
The role of CaMKII in heart failure pathophysiology has been
the subject of intense investigation since elevated CaMKII lev-
els were ﬁrst found in the myocardial tissue of heart failure
patients (Hoch et al., 1999; Kirchhefer et al., 1999). Increased
CaMKII expression and activity have since been mechanis-
tically linked to structural and electrophysiological dysfunc-
tion in numerous experimental models of severe cardiomy-
opathy and heart failure. However, deciphering precisely how
CaMKII is driving electrophysiologic dysfunction is made all the
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more difﬁcult by the extensive structural and electrophysiologic
remodeling that accompanies CaMKII hyperactivity in the failing
heart.
Target-speciﬁc roles of CaMKII in heart failure
Murine models of heart failure, CaMKII hyperactivity (over-
expression), and CaMKII regulation of RyR2 have provided a
wealth of information describing how CaMKII contributes to
both arrhythmogenesis and disease progression in cardiomyopa-
thy. Cardiac restricted overexpression of CaMKIIδC in the mouse
leads to heart failure, inducible arrhythmia, and premature death
(Zhang et al., 2003; Wagner et al., 2006). In these mice, acute
inhibition of CaMKII (via KN-93) prevents catecholaminergic
arrhythmia in vivo, and RyR2 dysfunction was implicated in this
arrhymogenic mechanism (Figure 3, mechanism 3) by a substan-
tial and CaMKII-dependent increase in SR Ca2+ leak, elevated
diastolic Ca2+, and DADs during Iso challenge (Sag et al., 2009).
SR-targeted inhibition of CaMKII with SR-AIP restored calcium
handling but worsened the heart failure phenotype suggesting that
otherCaMKIImechanisms are integral to pathological remodeling
(Huke et al., 2011). The phosphomimetic (S2814D) and non-
phosphorylatable (S2814A) RyR2 mutants developed by Wehrens
et al. (2004), have provided a powerful model for investigating
the role of CaMKII-dependent RyR2 regulation in a large num-
ber of acute and chronic diseases. Most recently, the knock-in
mice expressing these engineered RyR2 variants have provided
compelling evidence that CaMKII regulation of this protein con-
tributes to arrhythmogenesis in severalmodels of acquired disease.
The S2814D mouse slowly develops a heart failure phenotype and
is susceptible to sustained VT during epinephrine/caffeine chal-
lenge, and pressure-overload initiated prior to overt heart failure
also increased mortality due to arrhythmias in these mice (van
Oort et al., 2010). Genetic ablation of CaMKII-dependent RyR2
phosphorylation in the S2814A mouse provides protection from
pacing-induced arrhythmias after pressure-overload, slows the
development of contractile dysfunction, and reduces ventricular
remodeling and cellular SCR (van Oort et al., 2010; Respress et al.,
2012).
CaMKII has also been shown to contribute to heart failure
arrhythmias in large mammals. A series of studies in a rabbit
model of non-ischemic heart failure provides further mechanistic
evidence of the importance of CaMKII regulation of RyR2 in heart
failure arrhythmogenesis. In this model, total CaMKII expression
was elevated and the amount and activity of CaMKII localized to
RyR2 was increased in failing ventricular tissue, thus leading to
enhanced CaMKII-dependent phosphorylation of RyR2 (Ai et al.,
2005). Elevated SR Ca2+ leak was signiﬁcantly reduced with inhi-
bition of CaMKII but not PKA (Ai et al., 2005), and Iso-induced
SCR events (Ca2+ waves) were CaMKII-dependent (Curran et al.,
2010). Belevych et al. (2011) also described progressive patholog-
ical RyR2 dysfunction in a tachycardia-induced canine model of
heart failure. Mirroring changes in SR Ca2+ leak observed in the
rabbit, phosphorylation of RyR2 by CaMKII but not PKA was
increased after 1- and 16-months of tachycardic pacing. CaMKII
inhibition with KN-93 abolished proarrhythmic diastolic calcium
waves after 1 month but not 16-months. Instead, the increased
wave frequency at 16 months was attributed to increased ROS
production, which highlights the progressive nature of arrhythmia
mechanisms in heart failure, and suggests that CaMKII hyperac-
tivity may contribute more greatly to arrhythmogenesis early in
heart failure progression. Signiﬁcantly, the clinical importance of
CaMKIImodulation of RyR2was reinforced recentlywhen Fischer
et al. (2013a) demonstrated that CaMKII inhibition with KN-93
or AIP reduced SR Ca2+ leak in myocytes isolated from failing
human hearts.
CaMKII regulation of cardiac Na+ currents is another poten-
tial source of arrhythmogenic regulation during heart failure. The
mechanisms of this regulation are presented brieﬂy in Figures 2
and 3 and in detail elsewhere in this issue (see Grandi and Her-
ren, 2014), thus we only brieﬂy mention them in the context
of their importance in heart failure. INaL is increased in human
heart failure (Valdivia et al., 2005), and evidence from numerous
animal models suggests CaMKII inhibition normalizes INaL. In
a murine TAC-induced heart failure model, CaMKII inhibition
by AIP reversed increases in INaL, APD90, Iso-induced DAD fre-
quency, and SR Ca2+ leak (Toischer et al., 2013). In that study,
CaMKII phosphorylation of NaV1.5 was increased during decom-
pensated heart failure and application of ranolazine had a similar
result to CaMKII inhibition suggesting an important role for
CaMKII regulation of Na+ handling. Interestingly, myocytes from
pressure-overloaded hearts did not exhibit EADs in that study,
suggesting that Na+ does not carry the arrhythmogenic current.
Instead, the authors suggested that INaL was indirectly responsi-
ble for DADs by causing Na+-induced Ca2+-overload (Figure 2).
This idea is consistent with reports from several other studies.
Most recently Morotti et al. (2014) have suggested that Na+-
induced Ca2+-overload is a component of a positive feedback
loop that is quantitatively capable of eliciting CaMKII hyperac-
tivity, which in turn promotes arrhythmogenic outcomes and,
probably, further Na+ loading (Figure 2). Indeed, experiments
involving Na+ overload induced by anemone toxin (ATX-II, a
potent agonist of INaL) and an LQT3 mutation (N1325S), have
shown these maneuvers to be capable of inducing CaMKII acti-
vation and arrhythmia (Yao et al., 2011). Similar effects have been
observed during glycoside-induced Na+ overload (Gonano et al.,
2011; Ho et al., 2013), and arrhythmias resulting from glycoside
treatment were susceptible to both SR-targeted peptide inhibition
of CaMKII (Gonano et al., 2011) and ablation of CaMKII phos-
phorylation at RyR2 via S2814A mutagenesis (Ho et al., 2013).
Thus, it may again be that these Na+-dependent forms of arrhyth-
mogenesis converge at CaMKII-dependent regulation of RyR2. It
should be noted that some evidence in large mammals also sup-
ports a more direct arrhythmogenic role for CaMKII-dependent
regulation of Na+ currents (Figure 3B). In a canine model of
dyssynchronous heart failure with extensive electrophysiological
remodeling (Aiba et al., 2009), CaMKII expression, activity and
autophosphorylation were all increased, particularly in the late-
activated lateral LV wall (Chakir et al., 2008). Myocytes isolated
from these dogs exhibited shifted voltage-dependent availability,
enhanced intermediate inactivation, increased INaL and ranolazine
sensitive EADs (Aiba et al., 2013). Although inhibition studieswere
not performed in these dogs, Maltsev et al. (2008) had previously
identiﬁed CaMKII as an important regulator of INaL in the failing
canine heart.
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Regulation of LCCs by CaMKII presents a third potential
mechanism for proarrhythmic functionduringheart failure. How-
ever, as for INa the sites of CaMKII phosphorylation of LCCs
remain somewhat controversial, and this has caused mutagenic
approaches to investigating LCC-dependent mechanisms to be
more challenging. Similarly to TS, CaMKII regulation of ICaL
in heart failure is thought to elicit arrhythmia either by dis-
rupting repolarization and driving EADs (Figure 3B), or by
promoting cellular Ca2+ overload (Figures 2 and 3A). Again,
a complete treatment of CaMKII effects at ICa is provided else-
where in this issue (see the review from Bers), but brieﬂy, heart
failure-associated changes to LCC gating are quite similar to those
accompanying CaMKII regulation (Schröder et al., 1998; Dzhura
et al., 2000). Speciﬁcally, CaMKII elicits mode-2 gating in single
channels, and slows inactivation while hastening recovery from
inactivation of the macroscopic current (Guo et al., 2006). All of
these effects would be expected to promote EADs by reducing
repolarization reserve, independently promoting ICaL reactiva-
tion, or both (Anderson et al., 1994; Hashambhoy et al., 2010;
Koval et al., 2010). The most direct evidence for the ability of
CaMKII to elicit EADs via ICaL (in large mammal VMs), was
presented by Koval et al. (2010). In that study, the CaV1.2 β2a reg-
ulatory subunit was expressed in rabbit VMs, which increased ICa
facilitation and promoted EADs. Those effects were reversed by
peptide (CaMKIIN) or shRNA inhibition of CaMKII, and abla-
tion of the proposed CaMKII phosphorylation or binding sites
(Koval et al., 2010). Two caveats when extending these ﬁndings
to CaMKII hyperactivity in normal or failing myocytes are: (1)
the β2a subunit is probably a lesser component of LCCs in non-
diseased hearts, although its expression may be increased in heart
failure (Hullin et al., 2007), and (2) the slowed inactivation in
this study also increased total Ca2+ inﬂux without destabilizing
the AP. In vivo, the effect of this on whole-cell and SR Ca2+
overload could easily be as or more important than effects upon
repolarization.
Together these studies suggest that CaMKII-mediated ventric-
ular DADs and EADs exert a proarrhythmic inﬂuence in the
failing heart, and that the speciﬁc mode of arrhythmia initia-
tion and maintenance is likely dictated by the underlying etiology
and stage of disease development. The genetic tools available for
studying the role of CaMKII regulation of RyR2 in mice have
provided compelling evidence that this target is central to the
acute arrhythmogenic outcomes of CaMKII in the failing ven-
tricle, and this contention is largely supported by studies in large
mammals. Given the extensive structural and electrophysiological
remodeling accompanying heart failure, and relatively poor speci-
ﬁcity of small molecule inhibitors available for in vivo CaMKII
blockade, it is still not entirely clear how effective acute CaMKII
inhibition may be as an anti-arrhythmic strategy in heart fail-
ure. However, evidence published to date support an optimistic
outlook for potential therapeutic applications in this and other
acquired cardiac diseases.
Sinus node dysfunction in heart failure
Another series of recent studies, reviewed in this issue by Wu
and Anderson (2014), has suggested that oxidized-CaMKII (ox-
CaMKII) plays a critical role in SN dysfunction accompanying
heart failure, and that this involves pronounced structural remod-
eling of the SN. Swaminathan et al. (2011) ﬁrst observed that,
relative to non-diseased controls and heart failure patients with-
out SN dysfunction, heart failure patients with SN dysfunction
exhibit increased ox-CaMKII in right atrial tissue. This compre-
hensive study observed an analogous effect in a canine model of
pacing-induced heart failure, and utilized their previously devel-
oped model of Ang II-dependent oxidation/activation of CaMKII
to elicit and study the mechanisms of SN dysfunction in mice.
With this model ∼70% of mice develop sinus pause or exit block
after 3 weeks of Ang II infusion, and heart rate at rest and
during activity is blunted compared to untreated controls. SN
dysfunction was absent in AC3-I (cardiac speciﬁc) mice treated
with Ang II even though the pressor response to Ang II was
similar to WT. The observed dysfunction was associated with
increased apoptosis and ﬁbrosis within the SN, and structurally
based computational analysis suggests that the cell loss observed
experimentally may be sufﬁcient to explain both reduced SN ﬁr-
ing frequency, and episodes of exit block. One particularly elegant
component of this study showed that local adenoviral gene trans-
fer of theCaMKIIN inhibitory peptide (via painting of the SN)was
capable of preventing Ang II-driven SN dysfunction in WT mice.
Thus providing proof-of-principle that gene transfer of CaMKII-
inhibitors may be a viable therapeutic avenue for this speciﬁc heart
failure phenotype. A follow-up study from Luo et al. (2013) inves-
tigating SN dysfunction in a mouse model of combined insulin
deﬁciency and myocardial infarction, suggests that the mechanis-
tic cascade described by Swaminathan et al. (2011), may extend
to other cardiac conditions exhibiting pronounced oxidative
stress.
The role of oxidized CaMKII in driving structural remodeling
and dysfunction of the SN in response to oxidative stress high-
lights the ability of CaMKII to impact arrhythmogenic outcomes
via structural as well as functional changes. To date, the impact
of these tissue-level effects in CaMKII-mediated arrhythmia has
not been studied to the same extent as the effects on cellular elec-
trophysiology and Ca2+ handling. This aspect of CaMKII-driven
arrhythmia warrants further work, as some evidence suggests that
effects at this level may be important. For example, CaMKII
activity may exhibit regional heterogeneity in the heart (Chakir
et al., 2008). Even without considering this heterogeneity of kinase
action, transmural dispersionof repolarization is a predicted result
of CaMKII hyperactivity (Bers and Grandi, 2009) due exclusively
to its effects at Ito. Thus, putative roles for CaMKII in reentrant or
alternans-driven arrhythmias remain largely untested.
SUMMARY AND CONCLUSION
The ability of CaMKII to contribute to arrhythmia in mod-
els of cardiac disease that result from widely varying etiologies
is testament to the importance of this kinase in the control of
cardiac electrophysiology and calcium handling. It also suggests
that CaMKII exerts its proarrhythmic inﬂuence either by regu-
lating some convergent mechanism that is active in all of these
diseases, or by regulating a divergent range of proarrhythmic
mechanisms, which contribute to differing degrees in each dis-
ease. To date, the available mechanistic evidence suggests that
CaMKII-dependent regulation of diastolic SR Ca2+ release is
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the dominant cellular mechanism by which the kinase promotes
arrhythmia (Figure 3A). Of the various CaMKII targets capable
of driving this mechanism, RyR2 is the most clearly implicated.
This may in part be due to the quality of the tools available
for genetically manipulating CaMKII phosphorylation and reg-
ulation of RyR2, but it also suggests that developing exogenous
compounds capable of impairing the ability of CaMKII to phos-
phorylate RyR2 could constitute a broadly applicable therapeutic
strategy. Additional effects of CaMKII upon INa and ICaL may also
directly contribute to arrhythmia in some contexts (Figure 3B),
but in several of the examples described above it appears likely
that these effects again converge to elicit arrhythmia via SCR and
DADs (Figure 3A).
Both SCR and DADs are generally induced by some form of
acute Ca2+ overload, and it is probable that this partially explains
why CaMKII-dependent arrhythmia most often requires condi-
tions of tachycardia and, notably, β-adrenergic challenge. The
involvement of this additional signaling cascade brings in further
complexity that is almost certainly important in deﬁning the tran-
sition from stable to unstable electrophysiology. As suggested by
studies involving the Ankyrin B (+/−) mouse (DeGrande et al.,
2012), this may depend on less well-understood aspects of the sig-
naling network, such as local phosphatase balance. As such, strong
conclusions regarding any one CaMKII target as being crucial for
broad arrhythmia phenotypes should remain contentious until
these ﬁner details have been described with some clarity.
Tissue-level effects of CaMKII are also undeniably important,
as highlighted by SN dysfunction in heart failure, but beyond these
investigations, little direct evidence is available to describe how
CaMKII disrupts normal propagation of the cardiac AP. By incor-
porating regional heterogeneities in cellular electrophysiology,
computational modeling may aide in understanding these tissue
level effects provided sufﬁcient experimental data for parameter-
ization and validation are available. The reviews by Onal et al.
(2014), Greenstein et al. (2014), and Yaniv and Maltsev (2014)
offer a comprehensive survey of previous work modeling CaMKII
on the cellular and tissue levels.
CAVEATS AND IMPORTANT FUTURE DIRECTIONS
Even with the wealth of information that has amassed to describe
the role of CaMKII in cardiac arrhythmia over the last 20 years,
several key aspects either remain challenging or are otherwise
conspicuously absent from the existing literature. First, no study
has been capable of identifying a gain-of-function mutation in
CaMKII that is an independent risk for arrhythmogenic cardiac
disease, or indeed, any form of cardiac disease. This is surprising
given the data available from studies involving the various CaMKII
inhibitors. Second, a keyunrealizedobjective of theCaMKIIﬁeld is
tohavemore speciﬁcCaMKII inhibitors that canbe applied acutely
and in vivo (see the review from Pellicena and Schulman, 2014 in
this special issue). This is particularly true for studies of arrhyth-
mia, where such inhibitors would allow more straightforward
translation between cell-based experiments and arrhythmia out-
comes in intact animals, and perhaps eventually humans. Indeed,
as mentioned above, the tissue-level effects of CaMKII activity
and hyperactivity are poorly understood compared to the cellular
effects, and one reason for this is the lack of suitably speciﬁc small
molecule inhibitors. Third, as mentioned with respect to TS, the
use of murine myocytes for cell-based arrhythmia assays probably
biases the active mechanisms away from those occurring during
repolarization (EADs), and toward those that are active during
diastole (DADs). This is because the rapidly repolarizing murine
myocyte has markedly increased repolarization reserve, and cur-
rent dynamics during repolarization that are at least very different
to those in largemammals andhumans (Nerbonne,2004). As tech-
niques for differentiating and reprogramming h-IPSCs improve,
models based on this approach may offer a useful new tool for
studying the role of CaMKII in congenital arrhythmogenic dis-
eases at least. Examples of early studies in this direction have
recently appeared for CPVT (Di Pasquale et al., 2013) and TS
(Yazawa et al., 2011). However, concerns surrounding how well
these cells recapitulate adult cardiomyocyte Ca2+ handling are
particularly poignant in these and other Ca2+-related arrhythmo-
genic diseases. As such, the evidence supporting myocyte-speciﬁc
differentiation should be considered carefully and speciﬁcally for
any such future model.
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